FABP Biotech is a spin-off of the Oswaldo Cruz Foundation (Fiocruz) created to develop anti-helminth vaccines for animal use. The company holds the license to explore Fiocruz’s rights for the development and commercialization of vaccines and veterinary products based on Sm14, a member of the Fatty Acid Binding Proteins family.

FABP’s business model is grounded on strategic alliances to bring the Sm14-derived products in our pipeline to regulatory approval globally. Through partnerships with local companies well-versed in regional regulatory systems, we can bring cutting edge and innovative biotechnological solutions to the market.